Provectus Biopharmaceuticals to Discuss Outline of Phase 3 Clinical Trial Of PV-10 To Treat Melanoma on Conference Call
June 12 2014 - 6:00AM
Business Wire
Management Will Also Discuss Access to
ASCO-Presented Phase 2 Melanoma Data, Developments in Other Cancer
Indications and in PH-10 Use
Call Scheduled for Thursday, June 19, 2014 at 4
pm Eastern Daylight Time
Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT),
(http://www.pvct.com), a
development-stage oncology and dermatology biopharmaceutical
company, announced today that it will hold a conference call on
Thursday, June 19, 2014, at 4 pm Eastern Daylight Time.
Management will discuss the outline of the Company’s proposed
Phase 3 study of PV-10 in the treatment of melanoma, developments
in the use of PV-10 in other cancer indications, as well as PH-10
and news regarding its use. Management will also discuss its
potential plans to monetize its PV-10 and PH-10 assets with various
contemplated license and co-development transactions.
In addition, summary data from the PV-10 Phase 2 melanoma study
is expected to be available on clinicaltrials.gov prior to the
conference call.
Conference Call Thursday, June 19, 2014, at 4 PM EDT
The management of Provectus Biopharmaceuticals, Inc. will host a
conference call Thursday, June 19, 2014 at 4 PM Eastern. Those who
wish to participate in the conference call may telephone
877-407-4019 from the U.S. International callers may telephone
201-689-8337 approximately 15 minutes before the call. A webcast
will also be available at www.pvct.com.
A digital replay will be available by telephone approximately
two hours after the completion of the call until August 19, 2014,
and may be accessed by dialing 877-660-6853 from the U.S. or
201-612-7415 for International callers, and using the Conference
ID#13584727.
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals specializes in developing oncology
and dermatology therapies. Its novel oncology drug PV-10 is
designed to selectively target and destroy cancer cells through
intralesional administration, significantly reducing potential for
systemic side effects. Its oncology focus is on melanoma, breast
cancer and cancers of the liver. The Company has received orphan
drug designations from the FDA for its melanoma and hepatocellular
carcinoma indications. Its dermatological drug PH-10 also targets
abnormal or diseased cells, with the current focus on psoriasis and
atopic dermatitis. Provectus has recently completed Phase 2 trials
of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a
topical treatment for atopic dermatitis and psoriasis. Information
about these and the Company's other clinical trials can be found at
the NIH registry, www.clinicaltrials.gov. For additional
information about Provectus please visit the Company's website at
www.pvct.com or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: This press release contains
"forward-looking statements" as defined under U.S. federal
securities laws. These statements reflect management's current
knowledge, assumptions, beliefs, estimates, and expectations and
express management's current views of future performance, results,
and trends and may be identified by their use of terms such as
"anticipate," "believe," "could," "estimate," "expect," "intend,"
"may," "plan," "predict," "project," "will," and other similar
terms. Forward-looking statements are subject to a number of risks
and uncertainties that could cause our actual results to materially
differ from those described in the forward-looking statements.
Readers should not place undue reliance on forward-looking
statements. Such statements are made as of the date hereof, and we
undertake no obligation to update such statements after this
date.
Risks and uncertainties that could cause our actual results to
materially differ from those described in forward-looking
statements include those discussed in our filings with the
Securities and Exchange Commission (including those described in
Item 1A of our Annual Report on Form 10-K for the year ended
December 31, 2013, and in our Quarterly Report on Form 10-Q for the
quarter ended March 31, 2014), and the following:
- our determination, based on guidance
from the FDA, whether to proceed with or without a partner with a
phase 3 trial of PV-10 to treat locally advanced cutaneous melanoma
and the costs associated with such a trial if it is necessary;
- our determination whether to license
PV-10, our melanoma drug product candidate, and other solid tumors
such as liver cancer, if such licensure is appropriate considering
the timing and structure of such a license, or to commercialize
PV-10 on our own to treat melanoma and other solid tumors such as
liver cancer;
- our ability to license our dermatology
drug product candidate, PH-10, on the basis of our phase 2 atopic
dermatitis and psoriasis results, which are in the process of being
further developed in conjunction with mechanism of action studies;
and
- our ability to raise additional capital
in the event we determine to commercialize PV-10 and/or PH-10 on
our own, although our expectation is to be acquired by a
prospective pharmaceutical or biotech concern prior to
commercialization.
Provectus Biopharmaceuticals, Inc.Peter R. Culpepper, CFO,
COO866-594-5999 #30orPorter, LeVay & Rose, Inc.Marlon Nurse,
DM, SVP – Investor Relations212-564-4700orBill Gordon – Media
Relations212-724-6312
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024